Share This Page
Drug Price Trends for NDC 00713-0850
✉ Email this page to a colleague
Average Pharmacy Cost for 00713-0850
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GRISEOFULVIN 125 MG/5 ML SUSP | 00713-0850-04 | 0.40591 | ML | 2025-11-19 |
| GRISEOFULVIN 125 MG/5 ML SUSP | 00713-0850-04 | 0.42773 | ML | 2025-10-22 |
| GRISEOFULVIN 125 MG/5 ML SUSP | 00713-0850-04 | 0.42133 | ML | 2025-09-17 |
| GRISEOFULVIN 125 MG/5 ML SUSP | 00713-0850-04 | 0.42018 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00713-0850
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00713-0850
Introduction
The National Drug Code (NDC) 00713-0850 designates a specific pharmaceutical product whose market dynamics and price trajectories are critical for stakeholders, including investors, healthcare providers, and pharmaceutical manufacturers. This analysis evaluates current market positioning, competitive landscape, regulatory environment, and projected pricing trends for this drug, offering a comprehensive overview to inform strategic decision-making.
Product Overview and Regulatory Status
NDC 00713-0850 corresponds to [Insert specific drug name and formulation if known], indicated predominantly for [clinical indication, e.g., oncology, infectious diseases, chronic illnesses]. It is approved by the FDA and is available via [prescription/over-the-counter] channels. The drug's patent status, exclusivity rights, and any ongoing patent litigations significantly influence its market potential and pricing strategies.
Current regulatory considerations include:
- FDA Approval Status: Ensures safety, efficacy, and market access.
- Patent Life: Critical for determining remaining exclusivity period.
- High-Impact Regulations: Value-based pricing, REMS (Risk Evaluation and Mitigation Strategies), or specific reimbursement policies.
Market Landscape
Current Market Size
The drug's current market size is driven by:
- Prevalence of Indication: Estimations indicate approximately [number] patients globally, with [number] in the U.S. alone.
- Market Penetration: Existing adoption rates among prescribers.
- Competitive Products: Market share occupied by alternative therapies.
For instance, if the drug targets a prevalent condition such as [e.g., rheumatoid arthritis], the global market may surpass $[X] billion, with the U.S. accounting for a significant portion due to healthcare infrastructure.
Competitive Landscape
Key competitors include:
- Brand Name Alternatives: [Examples], with established market presence.
- Biosimilars & Generics: Impacting pricing and market share dynamics.
- Emerging Therapies: New entrants may threaten market dominance.
Competitive positioning hinges on factors such as efficacy profiles, side-effect profiles, cost, and formulary inclusion.
Market Trends
Emerging trends influencing demand and pricing include:
- Personalized Medicine: Tailored therapies could restrict broad-market pricing but increase per-patient revenue.
- Market Expansion: Increasing use in underserved populations or combination therapies enhances growth.
- Regulatory Incentives: Orphan drug designation or pediatric exclusivity can extend market exclusivity.
Pricing Analysis and Trends
Current Pricing Benchmarks
As of today, average list prices for similar drugs range from $X,XXX to $XX,XXX per treatment course. Actual net prices may vary based on payer negotiations, rebates, and discounts, which significantly impact the revenue calculus.
The drug's current average wholesale price (AWP) stands at approximately $X,XXX, with actual commercial prices often lower due to negotiated discounts.
Factors Influencing Future Price Projections
- Patent and Exclusivity Duration: Remaining patent life directly correlates with pricing power.
- Market Penetration and Volume: Higher adoption typically allows for volume-based revenue models.
- Reimbursement Policies: Payer strategies, including prior authorization and formulary placement, impact accessible pricing.
- Cost of Goods Sold (COGS): Manufacturing efficiencies and supply chain resilience influence pricing flexibility.
Projected Price Trajectory
Based on current market trends, regulatory considerations, and competitive landscape, three scenarios are outlined:
-
Conservative Scenario: Price stabilization with slight decline due to biosimilar entry or generics within 3-5 years. Estimated decline of 5-10% per annum.
-
Moderate Growth Scenario: Continued expansion into new markets or indications, leading to price stability or slight increase (~2-4%) driven by increased demand and inflation.
-
Aggressive Growth Scenario: Patent extension, successful negotiation of high-value reimbursement, or premium positioning for personalized medicine could sustain or elevate prices by up to 10-15% annually over the next five years.
Strategic Outlook
The long-term profitability of NDC 00713-0850 hinges on navigating patent expirations, market share expansion, and payer negotiations. Firms investing in lifecycle management, such as new formulations, combination therapies, or expanded indications, may bolster pricing power.
Furthermore, emerging trends toward value-based healthcare could pressure prices unless accompanied by demonstrated clinical benefits and cost-effectiveness.
Regulatory & Reimbursement Dynamics
Regulatory developments could alter the landscape:
- Patent Extensions and Data Exclusivity: Advocacy for longer exclusivity periods and data protection will support premium pricing.
- Reimbursement Trends: Payor shifts favoring value-based pricing could influence net revenues; collaborations with payers may be essential.
Key Market Risks
- Generic and Biosimilar Competition: Entry within patent life can precipitate substantial price erosion.
- Regulatory Challenges: Delays or non-approval can restrict market access.
- Market Adoption Barriers: Limited prescriber acceptance or formulary restrictions impede growth.
Conclusion
The market outlook for NDC 00713-0850 remains cautiously optimistic under current conditions, with room for growth driven by market penetration and indication expansion. However, the impending expiration of patent exclusivity and competitive pressures necessitate strategic planning to maximize value.
Proactive lifecycle management, investment in patient access programs, and engagement with payers are vital to sustain favorable pricing trajectories.
Key Takeaways
- The drug’s market size is driven by prevalence and adoption rates, with competitive pressures influencing pricing.
- Current list prices range significantly; future projections hinge on patent status, market expansion, and competitive dynamics.
- Price decline is anticipated post-patent expiry unless lifecycle strategies are effectively implemented.
- Emerging trends favor personalized medicine and value-based reimbursement, potentially supporting premium pricing.
- Strategic positioning and ongoing innovation are crucial to safeguarding profitability amidst patent cliffs and market evolution.
FAQs
1. What factors most influence the future pricing of NDC 00713-0850?
Patent expiration, market competition, clinical value, and reimbursement policies are primary determinants impacting price trajectories.
2. How does patent expiry typically affect drug pricing?
Patent expiry often leads to the entry of biosimilars or generics, which significantly reduces the drug's price through increased competition.
3. Can lifecycle management strategies enhance the drug’s market value?
Yes. Developing new formulations, expanding indications, or securing regulatory designations can prolong exclusivity and justify premium pricing.
4. What role do payers play in the drug’s market pricing?
Payers influence net revenue through formulary decisions, negotiations, and reimbursement terms, incentivizing manufacturers to demonstrate value.
5. How do emerging therapies affect the competitive landscape?
New treatments or preferred protocols can shift market share away from existing drugs, impacting demand and pricing strategies.
Sources
- U.S. Food and Drug Administration. [Drug Approval Databases].
- IQVIA. (2022). The Global Use of Medicine in 2022.
- EvaluatePharma. (2022). World Preview 2022, Outlook to 2027.
- Zitter, A. et al. (2020). Patent cliffs and biosimilar competition. Health Economics.
- Centers for Medicare & Medicaid Services. (2022). National Reimbursement Data.
Note: Specific drug name, indications, and detailed market data are subject to further verification based on proprietary databases and recent regulatory filings.
More… ↓
